Anemia as a risk factor and therapeutic target in heart failure

Anemia has recently been recognized as an important comorbid condition and potentially novel therapeutic target in patients with heart failure (HF). Anemia is common in HF patients, with a prevalence ranging from 4% to 55% depending on the population studied. Multiple potential mechanisms of interac...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2004-09, Vol.44 (5), p.959-966
Main Authors: Felker, G. Michael, Adams, Kirkwood F., Gattis, Wendy A., O'Connor, Christopher M.
Format: Article
Language:English
Subjects:
Anemia
Anemia - epidemiology
Anemia - physiopathology
Anemia - therapy
Anemias. Hemoglobinopathies
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Clinical outcomes
Clinical trials
Comorbidity
Disease
Diseases of red blood cells
Drug therapy
Erythropoietin - pharmacology
Erythropoietin - therapeutic use
Heart
Heart - drug effects
Heart failure
Heart Failure - epidemiology
Heart Failure - physiopathology
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Hematocrit
Hematologic and hematopoietic diseases
Humans
Hypertension
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - therapy
Medical sciences
Medicare
Mens health
Mortality
Population
Recombinant Proteins
Renal Dialysis
Risk Factors
Studies
Thrombosis
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anemia has recently been recognized as an important comorbid condition and potentially novel therapeutic target in patients with heart failure (HF). Anemia is common in HF patients, with a prevalence ranging from 4% to 55% depending on the population studied. Multiple potential mechanisms of interaction exist between anemia and the clinical syndrome of HF, including hemodilution, inflammatory activation, renal insufficiency, and malnutrition. A growing body of literature from observational databases and clinical trials suggests that anemia is an independent risk factor for adverse outcomes in patients with HF. Although preliminary data suggest that treatment of anemia may result in significant symptomatic improvement in HF, aggressive treatment of anemia may also be associated with increased risk of hypertension or thrombosis. Multiple ongoing studies will provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2004.05.070